Association between immune checkpoint inhibitor treatment in individuals with cancer and risk of hospitalisation after SARS-CoV-2 infection: a population-based retrospective cohort study

Carrie Ye, Meng Lin, Finlay A. McAlisterBMJ 2025 · DOI

Abstract

Introduction: Immune checkpoint inhibitor (ICI)-treated patients exhibit greater serological conversion rates following COVID-19 vaccinations compared with those receiving cytotoxic chemotherapy, but it is unknown whether those receiving ICIs—which restore cellular immunocompetence—may be at higher or lower risk of severe SARS-CoV-2 infection.

Methods: We conducted a retrospective cohort study of individuals with a prior diagnosis of cancer and SARS-CoV-2 infection from March 2020 to June 2021 in Alberta, Canada. Propensity score matching was used to compare outcomes in ICI-treated and non-ICI-treated individuals. Outcomes included all-cause death, all-cause hospitalisations, and COVID-19 hospitalisations within 30 days of a positive test.

Results: Among 8,938 individuals with cancer and COVID-19, 237 were receiving ICI therapy. ICI treatment was associated with a higher risk of 30-day all-cause hospitalisations (adjusted OR [aOR] 1.58, 95% CI 1.13 to 2.21, p=0.007), but not COVID-19 hospitalisations (aOR 1.41, 95% CI 0.97 to 2.05, p=0.07) or 30-day all-cause mortality (aOR 0.61, 95% CI 0.35 to 1.06, p=0.08).

Conclusions: Cancer patients treated with ICIs are at higher risk of hospitalisation after SARS-CoV-2 infection. Clinicians should maintain heightened awareness for this vulnerable population during viral surges.

Introduction: The Double-Edged Sword of Immune Activation

Most traditional cancer treatments, such as chemotherapy, are immunosuppressive, leaving patients highly vulnerable to infections. Immune checkpoint inhibitors (ICIs) operate differently by blocking the "brakes" on the immune system (e.g., PD-1 or CTLA-4), allowing T-cells to attack tumors. While this restores immune competence, a hyper-active immune system can also trigger "cytokine storms" or immune-related adverse events (irAEs) during a viral infection. This study investigates whether ICIs help or hinder a patient’s recovery from COVID-19.

Methods: A Population-Level "Twin" Study

The researchers utilized Alberta’s single-payer healthcare system to link province-wide databases, including the Alberta Cancer Registry and provincial laboratory data. To account for the fact that ICI patients often have more advanced-stage cancers, the study employed Propensity Score (PS) Matching. This statistical technique created a "twin" for every ICI patient from a pool of non-ICI cancer patients based on age, sex, cancer type, stage, and comorbidities.

Table 1: Baseline characteristics of the unmatched and propensity score-matched cohorts.

Key Results: The Hospitalization Paradox

The study identified a "hospitalization paradox": while ICI patients were significantly more likely to be hospitalized for any reason, the risk for COVID-specific hospitalization and death did not reach statistical significance after full adjustment.

  • All-Cause Hospitalization: ICI treatment was associated with a 58% higher risk (aOR 1.58, p=0.007).
  • Mortality Trends: Interestingly, the adjusted odds ratio for mortality was 0.61 (p=0.08). While not statistically significant, it hints at a trend where a boosted immune system might actually help prevent death from the virus, even if the systemic reaction necessitates hospital monitoring.
  • The Importance of Matching: Before matching, the ICI group appeared to have nearly double the mortality rate (11.4% vs 5.9%). However, once adjusted for cancer stage and age, this gap narrowed significantly, highlighting that cancer severity—rather than the drug itself—is the primary driver of mortality.
Table 3: Adjusted odds ratios for 30-day outcomes comparing ICI treatment to no ICI treatment across different adjustment models.

Discussion and Future Directions

The findings suggest that the increased hospitalization risk may be driven by the infection triggering immune-related adverse events rather than severe viral pneumonia alone.

Limitations: The study lacked data on functional status (ECOG scores), which is a major predictor of health outcomes. Additionally, while 237 ICI patients represent a significant cohort, the sample size may still be too small to detect subtle differences in mortality rates.

Future Work: Researchers suggest investigating whether this hospitalization surge occurs with other endemic viruses like influenza and exploring the long-term impact of ICIs on "Long COVID" symptoms. For now, the takeaway for clinicians is clear: patients on ICI therapy require heightened clinical vigilance during any viral surge.

Summary updated

Abstract

Introduction Immune checkpoint inhibitor (ICI)-treated patients exhibit greater serological conversion rates following COVID-19 vaccinations compared with those receiving cytotoxic chemotherapy and healthy subjects, but whether those receiving ICIs, which unlike most cancer therapies restore cellular immunocompetence, may be at higher or lower risk of severe SARS-CoV-2 infection. It is unknown. Research design and methods We conducted a retrospective cohort study of individuals with a prior diagnosis of cancer and SARS-CoV-2 infection from March 2020 to June 2021 in Alberta, Canada. Propensity score matching was used to compare outcomes in ICI-treated and non-ICI-treated individuals. Outcomes included all-cause death, all-cause hospitalisations, and COVID-19 hospitalisations between 2 days prior to and 30 days after the index positive SARS-CoV-2 reverse transcription PCR (RT-PCR) test date. Results There were 8938 individuals with cancer and a positive SARS-CoV-2 RT-PCR test, including 237 being treated with ICI at the time of infection. ICI treatment was associated with higher risk of 30-day all-cause hospitalisations (adjusted OR, aOR 1.58, 95% CI 1.13 to 2.21, p=0.007), but not COVID-19 hospitalisations (aOR 1.41, 95% CI 0.97 to 2.05, p=0.07) and 30-day all-cause mortality (aOR 0.61, 95% CI 0.35 to 1.06, p=0.08). Conclusions Individuals with cancer treated with ICIs are at higher risk of hospitalisation after SARS-CoV-2 infection compared with individuals with cancer not treated with ICI therapy. These results should alert clinicians and public health officers to this particularly vulnerable population in future pandemics, and future research should examine the impact of ICI in patients with endemic viral infections.
BibTeX
@inproceedings{ye2025association,
  author = {Carrie Ye and Meng Lin and Finlay A. McAlister},
  title = {{Association between immune checkpoint inhibitor treatment in individuals with cancer and risk of hospitalisation after SARS-CoV-2 infection: a population-based retrospective cohort study}},
  booktitle = {BMJ},
  year = {2025},
  doi = {10.1136/bmjconc-2025-000020},
}
Figure